GP-03 Synthesis and Antimicrobial Activity of Novel Puromycin Analogs
Start Date
31-3-2023 10:30 AM
End Date
31-3-2023 12:30 PM
Document Type
Poster
Abstract
Synthesis and Antimicrobial Activity of Novel Puromycin Analogs.
Adrianna Cody,a Amy R. Messersmith,a Joshua V. Ruppel,b and Giuseppe Guminaa*
aDepartment of Pharmaceutical and Administrative Sciences, Presbyterian College School of Pharmacy, 307 N. Broad Street, Clinton, South Carolina 29325, USA.
bDivision of Natural Science and Engineering, USC Upstate, 800 University Way, Spartanburg, South Carolina 29303, USA.
Puromycin is an antitumor antibiotic that uses early protein chain termination to induce cell death and has the potential to prove useful in the treatment of infections like multidrug resistant staphylococcus aureus (MRSA). However, a major drawback of puromycin is its metabolism to the nephrotoxic compound puromycin aminonucleoside (PAN).
To solve such issue, we designed and synthesized analogs that are equally or more active against different microorganisms, nonnephrotoxic, and chemically stable. This poster describes the synthesis of a promising new puromycin analog with antimicrobial activity against both Gram-positive and Gram-negative strains of clinical interest. Updated structure-activity relationships for modified puromycin-based molecules will also be presented.
Key Words: puromycin, nucleoside, antimicrobial
GP-03 Synthesis and Antimicrobial Activity of Novel Puromycin Analogs
Synthesis and Antimicrobial Activity of Novel Puromycin Analogs.
Adrianna Cody,a Amy R. Messersmith,a Joshua V. Ruppel,b and Giuseppe Guminaa*
aDepartment of Pharmaceutical and Administrative Sciences, Presbyterian College School of Pharmacy, 307 N. Broad Street, Clinton, South Carolina 29325, USA.
bDivision of Natural Science and Engineering, USC Upstate, 800 University Way, Spartanburg, South Carolina 29303, USA.
Puromycin is an antitumor antibiotic that uses early protein chain termination to induce cell death and has the potential to prove useful in the treatment of infections like multidrug resistant staphylococcus aureus (MRSA). However, a major drawback of puromycin is its metabolism to the nephrotoxic compound puromycin aminonucleoside (PAN).
To solve such issue, we designed and synthesized analogs that are equally or more active against different microorganisms, nonnephrotoxic, and chemically stable. This poster describes the synthesis of a promising new puromycin analog with antimicrobial activity against both Gram-positive and Gram-negative strains of clinical interest. Updated structure-activity relationships for modified puromycin-based molecules will also be presented.
Key Words: puromycin, nucleoside, antimicrobial